Close Menu

NEW YORK (GenomeWeb) – Somalogic and DeCode Genetics announced today that they are collaborating on a proteomic analysis of up to 40,000 of DeCode's patient samples.

The analysis will use Somalogic's SomaScan platform, which measures the levels of 5,000 proteins using the company's Somamer affinity reagents. According to the firms, Reykjavik-based DeCode will use the data gathered through this analysis for drug discovery and development work, while Boulder, Colorado-based Somalogic will use the findings to develop clinical applications of the SomaScan platform.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.